From 1 July 2011 prescribers will be permitted to prescribe ezetimibe or ezetimibe with simvastatin without regard to the dose of statin that is co-prescribed:1
- a patient is now considered to have inadequate control after ≥ 3 months of treatment at a maximum tolerated dose of a statin. The requirement of a statin dose ≥ 40 mg daily has been removed.2
- prescribers may now use their clinical judgment when reducing the dose of a statin in response to an adverse effect. The requirement to reduce the dose of a statin to < 20 mg daily has been removed.2
- Pharmaceutical Benefits Advisory Committee. Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) in March 2011 relating to the listing of drugs on the Pharmaceutical Benefits Scheme. Canberra: Australian Government Department of Health and Ageing, 2011. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-outcomes/2011-03 (accessed 3 May 2011).
- Department of Health and Ageing. PBS for Health Professionals. Canberra, 2011. http://www.pbs.gov.au/ (accessed 9 May 2011).